The aim of this study was to investigate whether selected growth factors (VEGF, FGF), lectins (Galectin-1, Galectin-3), protein (Fascin), or cytokine (TNF-α) measured in the serum of patients with disseminated endocrine neoplasms could serve as potential biomarkers for active disease or tumor recurrence. This evidence concerns the gene FSCN1 and neoplasm.